Previous 10 | Next 10 |
ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS PR Newswire TOKYO and CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eis...
EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING PR Newswire TOKYO and CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai")...
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that three additional detailed...
TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai presented new analy...
The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regions Phase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral spinal fluid (CSF) throughout the open-label l...
2023-03-25 15:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-03-23 13:56:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won’t do it any favors, specific stalwarts can get the ...
CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment ...
2023-03-22 18:05:49 ET Editor's note: This article was updated at 520p to reflect a second vote from the panel. An FDA advisory panel gave mixed signals Wednesday afternoon in two votes regarding Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyot...
2023-03-22 17:06:31 ET An FDA advisory panel voted 9-0 that the data on Biogen ( NASDAQ: BIIB ) and Ionis Pharmaceuticals ( IONS ) amyotrophic lateral sclerosis (ALS) drug tofersen likely predicts it benefit. The recommendation from the Peripheral and Central...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...